Cancer Cell Panel & In Vitro Oncology Assays

Overview

We also offer a diverse in vitro screening panel of over 378 authenticated, well-validated human cancer cell lines across 21 organs/tissues. The cancer cell panel provides powerful tools for cancer research and drug discovery. Key features of the WuXi cancer cell panel include:

  • High quality cell banking system: mycoplasma-proof and STR verified
  • Single agent and combination compound screening for potency (% inhibition & IC50) and synergy (combination index CI)
  • Professional design with stringent quality control of study results
  • A database of cell growth curve and Standard of Care (SoC) validation data provides guidance for cell model selection
  • Fast study turnaround
  • A comprehensive range of functional assays

Large Scale Human Cancer Cell Lines for Cell Panel Services

A wide range of 378 human cancer cell lines is available for oncology drug discovery programs. The cell banking system is a two-tiered banking system with mycoplasma testing and STR validation. Established cell growth data and standard of care profiling enhance the quality of study. The table shows the distribution of 378 human cancer cell lines, sorted by the origins of derived organs/tissues.

Cancer Cell Line

Number of Cell Lines

% of Total

Lung

120

31.7

Breast

66

17.5

Hematopoietic/lymphoid tissue

44

11.6

Large intestine

35

9.3

Liver

15

4.0

Skin

11

2.9

Connective/soft tissue

11

2.9

Stomach

9

2.4

Pancreas

9

2.4

Brain

9

2.4

Kidney

8

2.1

Bone

7

1.8

Upper aerodigestive tract

7

1.8

Bladder

6

1.6

Ovary

6

1.6

Prostate

5

1.3

Thyroid

3

0.8

Synergistic effects of Compound X with Ibrutinib in TMD8

Synergistic effects of Compound X with Ibrutinib in TMD8

Potency Correlation of Compounds (kinase assay & cell proliferation assay)

Potency Correlation of Compounds (kinase assay & cell proliferation assay)

Cell line-derived xenograft (CDX) tumor models

Overview

  • A large collection of cell line-derived xenograft (CDX) tumor models
    -183 validated models, SOC data available
  • World leading imaging based orthotopic/metastatic CDX platform
    -28 models covering 16 tumor types

Cell Line-Derived Xenograft (CDX) Tumor Models: 183

Tumor Types

Cell lines

Bladder

T24/83, RT112/84, UM-UC-3, J82

Brain

U87*, LN-229*

Breast

Cal51*, BT-474*, HCC1954*, MDA-MB-231*, MDA-MB-468*, HCC1806*, MCF7*, HCC1937, MDA-MB-436*, SUM-52Pe, JIMT-1*, MDA-MB-361*, HCC-70, SUM 159PT, MFM-223, T47D*, HCC1428, Z-75-1*

Cervical

SW756

Colorectal

Colo205*, HT29, HCT-116*, HCT-15*, LS180*, LS174T*, SW620*, HT55*, DLD-1, Lovo, COLO-320DM, RKO, Caco-2, T84, WiDr, SW480, SW 48, LS411N, COLO 201

Duodenal

HuTu80

Esophageal

T.Tn, OE21*

Gastric

NUGC4*, SNU-1, SNU-16*, MCG-803, NCI-N87*, SNU-5, MKN45*, HS 746T

Head & Neck

Cal 27, RPMI2650, SCC-9, Fadu*

Leukemia

HEL 92.1.7*, MV4-11*, CCRF-CEM, HL-60, K562, KG-1, MOLT-4, Kasumi-1*, Nalm-6*, THP-1, SET-2, PL-21, MLK-1

Lymphoma

Daudi*, SU-DHL-2*, SU-DHL-10, Granta-519, Maver-1, Mino, NAMALWA, Raji, Ramos, RL, WSU-DLCL2, Z-138, U379, DoHH2, Farage*, Pfeiffer, REC-1*, OCI-LY10, TMD-8*

Tumor Types

Cell lines

Liver

BEL-7404*, Hep3B*, Huh 7*, HepG2, SNU-182, QGY-7703, SNU-398, JHH-7*, MHCC97H*

Lung

NCHI-H1650, NCI-H226, NCI-H460, PC9*, A549*, Calu-1, Calu-6*, EBC-1, A427, NCI-H647, MSTO-211H, NCI-H292, NCI-H322, NCI-H358*, NCI-H441, NCI-H520, NCI-H1957*, NCI-H2228, SK-MES-1, NCI-H1229, HCC-827*, HCC400646, NCI-H1703, NCI-H727, NCI-H2122*, DV-90, NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77, Calu-3, NCI-H2170

Melanoma

A375*, SK-MEL-24, SK-MEL-28, COLO 829*, SK-MEL-5, MDA-MD-435S

Myeloma

KMS-28BM, KMS-11, MOLP-8*, NCI-H929, RPMI 8226*, MM.1S*

Neuroblastoma

CHP-134*, SK-N-AS*, BE(2)-C*, SH-SY5Y

Ovary

A2780*, SK-OV-3*, ES-2*, OVCAR-3, TOV21G

Pancreas

BxPC3*, Mia-pa-ca-2*, KP4, PANC-1*, CAPAN-1, Panc 02.13*

Prostate

PC-3*, DU145, LNCap*, VCaP, 22RV.1


Renal

786-O* ACHN, Caki-1, SK-NEP-1, A498

Sarcoma

HT1080, A673, KHOS/NP, 143B, SJSA-1*, SAOS-2, A204, G401

Skin

A431*

*: validated with SOC compound

28 Luciferase Labelled Orthotopic/Metastatic Tumor Models

  • Cover 16 tumor types
  • Bioluminescent imaging system in SPF barrier
tumor types / cell lines
O: orthotopic model  M: metastatic mode  S: validated with SOC

Immuno-oncology

One stop service to enable cancer immunotherapy

Outstanding Platform to Enable Cancer Immunotherapy with One Stop Service

  • Immunological function assessment
  • Tumor microenvironment analysis
  • In vivo efficacy evaluation on animal models
  • NGS to understand TCR/BCR Repertoire
  • Patient TILs analysis

Immuno-oncology In Vitro Functional Assays

  • Immune cell activation assays
    – T/B/NK cell activation
  • Macrophage differentiation assays
    – M1/M2 macrophage differentiation
    – DC differentiation
    – MDSC induction
  • T cell polarization assays
    – Treg/Th1/Th2/Th17 differentiation
  • T cell cytotoxicity assay
    – Cytotoxic T lymphocyte assay (OT-1 system)
  • Mixed Lymphocyte Reaction
  • Immune cell suppressive assay
    – MDSC/Treg/Tumor-T suppressive assay
  • Antibody mediated immunological assay
    – ADCC/CDC/ADCP

Assay

WuXi capibility (Human/Mouse)

Call activation

T cell

Yes (H/M)

B cell

Yes (H)

NK cell

Yes (H)

Cell differentiation/

polarization

M1/M2 macrophage

Yes (H/M)

MDSC

Yes (H)

DC

Yes (H/M)

Treg, Th1, Th2, Th17 polarization

Yes (H)

Mixed Lymphocyte Reaction

DC co-culture with T

Yes (H/M)

Suppressive Assay

MDSC suppressive assay

Yes (H)

Treg suppressive assay

Yes (H)

Tumor cell+immune cell co-culture

Yes (H)

Cell cytoxicity

Cytotoxic T lymphocyte assay (OT-1 system)

Yes (M)

NK cytotoxicity

Yes (H)

ADCC, ADCP

Yes (H)

CDC

Yes (H)

Cell exhaustion

T cell exhaustion

Yes (M)

Immuno-oncology In Vitro Technical Competence

Immune cell profiling in tumor infiltrating leukocyte (TIL) and other tissues (spleen, blood, lymph node, liver, etc.) profiling: (1) Immune cell population analysis (T, B, NK, DC, Myeloid, Macrophage, Granulocyte, CD4+T, CD8+T, Treg, Th1/2/17, naïve/memory/effector T, g/mMDSC, M1/M2, etc.) (2) Functional and intracellular marker analysis (PD-1, PD-L1/2, CTLA-4, TIM-3, LAG-3, OX40, 4-1BB, ICOS, Ki-67, IL-2, IL-17, IFNγ, TNFα, Granzyme B, etc.)

Biomarker

  • Soluble biomarker – ELISA, ELISPOT
  • Cell-based biomarker – FACS
  • Tissue-based biomarker – Multiplex IHC
  • Gene expression profiling-RNAseq, Nanostring

Tumor Infiltrating Lymphocytes (TILs) Analysis on Human and Murine Tumor Tissues

  • CD4, CD8, MDSC, M1/M2, DC cell, NK cell, B cell
  • PD1, TIM3, LAG3, OX40, 4-1BB
  • Treg, Th1,2,3,17 …

In Vivo Efficacy Evaluation on Animal Models Syngeneic Murine Models

  • Immune-checkpoint humanized models
  • Immune-Avatar humanized models PBMC humanized models
  • HSC humanized models

TM (Tumor Microenvironment) Analysis for Immunoscore by FACS, IHC and IF

CTLs, NK, Tregs, MDSC, TAM, etc.’

Lymphoid Tissue and Peripheral Blood Analysis

  • Immune cell populations and subsets – frequency, activation, and differentiation
  • Cytokine and chemokine analysis
  • Anatomical localization ofin vivo anti-tumor immune responses

Adoptive T Cell Therapy